HC Wainwright Issues Negative Estimate for DMAC Earnings

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings estimates for DiaMedica Therapeutics in a note issued to investors on Friday, May 8th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.19) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.25) EPS and FY2030 earnings at $0.04 EPS.

A number of other research firms have also weighed in on DMAC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered shares of DiaMedica Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, DiaMedica Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Trading Up 2.1%

DiaMedica Therapeutics stock opened at $6.45 on Tuesday. The firm’s 50 day simple moving average is $6.80 and its 200 day simple moving average is $7.56. The firm has a market capitalization of $347.53 million, a PE ratio of -9.08 and a beta of 0.99. DiaMedica Therapeutics has a 1-year low of $3.47 and a 1-year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02).

Hedge Funds Weigh In On DiaMedica Therapeutics

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of DiaMedica Therapeutics in the 4th quarter worth $29,000. Russell Investments Group Ltd. bought a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth $27,000. Farther Finance Advisors LLC purchased a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at $34,000. Bank of America Corp DE boosted its stake in shares of DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares in the last quarter. Finally, Strs Ohio boosted its stake in shares of DiaMedica Therapeutics by 19.7% in the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.